https://kuraoncology.com/wp-content/uploads/Erba_video_1_thumbnail.png
1018
2000
David Anderson
/wp-content/uploads/kura-logo-registered-blue.svg
David Anderson2023-12-20 16:26:052023-12-20 16:43:11Dr. Erba discusses the KOMET-001 Phase 1b safety and tolerability data of ziftomenib, a menin inhibitor, for patients with R/R NPM1-m AML
https://kuraoncology.com/wp-content/uploads/Erba_video_2_thumbnail.png
1166
2292
David Anderson
/wp-content/uploads/kura-logo-registered-blue.svg
David Anderson2023-12-19 16:47:432023-12-20 16:48:26Dr. Erba offers insight into the KOMET-007 Phase 1 trial and rationale for investigating ziftomenib in combination with standards of care for the treatment of patients with newly diagnosed or R/R NPM1-m or KMT2A-r AML
https://kuraoncology.com/wp-content/uploads/Erba_video_3_thumbnail.png
1172
2288
David Anderson
/wp-content/uploads/kura-logo-registered-blue.svg
David Anderson2023-12-18 16:50:412023-12-20 16:50:53Dr. Erba explains the different combinations KOMET-008 will evaluate and how it differs from KOMET-007
https://kuraoncology.com/wp-content/uploads/Erba_video_4_thumbnail.png
1166
2292
David Anderson
/wp-content/uploads/kura-logo-registered-blue.svg
David Anderson2023-12-17 16:52:422023-12-20 16:52:53“Project Optimus encourages optimal biological dosing rather than maximally tolerated dosing.” — Harry Erba, MD, PhD
https://kuraoncology.com/wp-content/uploads/Erba_video_5_thumbnail.png
1172
2286
David Anderson
/wp-content/uploads/kura-logo-registered-blue.svg
David Anderson2023-12-16 16:56:012023-12-20 16:56:13Dr. Erba provides an overview of the KOMET clinical trial program
https://kuraoncology.com/wp-content/uploads/Fathi_r2_long_thumbnail.png
640
1137
eallison
/wp-content/uploads/kura-logo-registered-blue.svg
eallison2023-09-19 10:54:002023-09-19 10:57:37Dr. Fathi presents the latest KOMET-001 data
https://kuraoncology.com/wp-content/uploads/Screenshot-2023-08-23-at-6.38.57-PM.png
1172
2338
David Anderson
/wp-content/uploads/kura-logo-registered-blue.svg
David Anderson2023-08-23 17:17:322023-08-24 08:43:04Evaluating ziftomenib in combinations for patients who are newly diagnosed or relapsed/refractory NPM1m or KMT2Ar AML
https://kuraoncology.com/wp-content/uploads/Fathi_testing_thumbnail.jpg
235
422
eallison
/wp-content/uploads/kura-logo-registered-blue.svg
eallison2023-08-08 16:40:522023-08-23 17:06:48NPM1 mutations in acute myeloid leukemia: actionable mutations to inform treatment decisions with clinical trials
https://kuraoncology.com/wp-content/uploads/Mechanism-of-action-for-investigational-menin-inhibitors-including-ziftomenib.jpg
235
422
eallison
/wp-content/uploads/kura-logo-registered-blue.svg
eallison2023-08-08 16:12:302023-08-23 17:07:13Mechanism of action for investigational menin inhibitors, including ziftomenib
https://kuraoncology.com/wp-content/uploads/Video-2-thumbnail.png
235
422
eallison
/wp-content/uploads/kura-logo-registered-blue.svg
eallison2023-06-16 13:47:032023-08-23 17:06:30Can you give a brief overview of unmet medical needs within NPM1-mutated acute myeloid leukemia?
Scroll to top